Camurus’ Interim Report January-March 2026

Q1 2026 revenues fell 5% to SEK 533 million, but were up 3% at constant exchange rates, while royalties rose 44% to SEK 106 million. Operating profit declined 30% to SEK 168 million and profit before tax fell 28% to SEK 184 million, but the company said performance is on track for full-year guidance. The FDA also accepted the Oclaiz NDA, adding a regulatory catalyst.

Analysis

The key read-through is that this is a quality-of-earnings quarter, not a demand thesis failure. Product revenue softness looks like a timing issue, while royalty growth and an accepted FDA filing shift the mix toward higher-margin, lower-capital-intensity cash flows; that usually deserves a higher multiple than a flat top-line print would imply. The market should focus on the fact that cash remains ample, so the company can absorb a few more quarters of launch-related volatility without financing risk.

The second-order setup is a catalyst stack over the next 3-9 months: regulatory acceptance de-risks one leg of the pipeline, but the real inflection will be whether commercial execution converts into sustained prescription traction. If the launch ramps cleanly, competitors with older standards of care may face a prolonged share bleed rather than a one-quarter disruption, especially if payers view the new option as a differentiated step-up. Conversely, any label questions, manufacturing hiccup, or payer resistance would hit the multiple faster than the P&L because the stock is likely being priced on forward launch optionality.

Contrarian view: the market may be underestimating how much of the current valuation is anchored in regulatory milestones rather than near-term sales. That creates asymmetry—good news from the FDA keeps the rerating alive, but mediocre commercial data could compress expectations quickly because the revenue base is still not broad enough to absorb disappointment. The cleanest tell over the next quarter is whether royalties continue compounding while product sales stabilize; if not, this could be a classic "guidance intact, model too high" setup where the headline optimism masks weakening underlying demand velocity.

Key Decisions for Investors

• If liquid and borrowable, buy 1-3 month call spreads into launch-related catalysts; risk/reward is attractive if the market starts to price a successful commercial ramp before hard sales data confirms it.
• Short competing legacy franchises or smaller-name peers exposed to the same indication on any strength in the next 2-6 weeks; the regulatory de-risking can shift share expectations faster than actual scripts.
• Use a pairs trade: long the name against a basket of slower-growth biotech peers with weaker balance sheets, betting that cash-rich, royalty-supported growth deserves a premium through the next two quarters.
• If the stock gaps on FDA news, fade only with tight risk controls—commercial proof is still the main swing factor, so upside can persist for months if early uptake data is even modestly positive.